Intelligent Ultrasound Group PLC Change of Auditor (3517A)

TIDMIUG

RNS Number : 3517A

Intelligent Ultrasound Group PLC

23 September 2022

Intelligent Ultrasound Group plc

(the "Group" or the "Company" or "Intelligent Ultrasound")

Change of Auditor

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that, following a competitive and comprehensive tender process, Evelyn Partners Limited ("Evelyn") will be appointed as the Company's auditor for the year ending 31 December 2022. The Company intends to put the appointment of Evelyn as auditor to a vote of shareholders at the Company's next Annual General Meeting.

Following the tender process and the decision to appoint Evelyn, Deloitte LLP has resigned. The Board wishes to take this opportunity to extend appreciation to Deloitte for its services rendered to the Company.

As required by section 519 of the Companies Act 2006, Deloitte has deposited a statement with the Company confirming that there are no circumstances in connection with its resignation as auditor that should be brought to the attention of the Company's shareholders and the reason for their resignation was as a result of the tender process.

Enquiries:

 
 Intelligent Ultrasound Group                                          www.intelligentultrasound.com 
  plc 
 Stuart Gall, CEO                                                           Tel: [phone] 
 Helen Jones, CFO 
 
 Cenkos Securities                                                          Tel: [phone] 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Dale Bellis / Julian Morse (Sales) 
 
 Walbrook PR                        Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                Mob: [phone] 
 
 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,400 simulators have been sold to c. 700 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based

anatomy   highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

www.intelligentultrasound.com

NOTE: ScanNav Anatomy PNB is CE approved, but not yet available for sale in the US or any other territory requiring government approval for this type of product.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPGZGZLDZMGZZM

(END) Dow Jones Newswires

September 23, 2022 02:01 ET (06:01 GMT)